Organism: Plasmodium falciparum
Organism: human
Strain: 3D7
CellLine: CDPK1-HA-parasites
CellLine: PKGT618Q-parasites
OrganismPart: red blood cells
OrganismPart: infected RBCs
SampleTreatment: sorbitol treatment
SampleTreatment: saponin treatments (0.1%)
SampleTreatment: saponin treatment (0.1%) for 10 min
SampleTreatment: treatment with vehicle or Compound 2 (2 μM, 60 min)
SampleTreatment: saponin in PBS supplemented with protease and phosphatase inhibitors
ReductionReagent: DTT
AlkylationReagent: iodoacetamide
CleavageAgent: trypsin
Label: carboxyamidomethyl (C)
Label: oxidation (M)
Label: phosphorylation (S/T/Y)
Modification: oxidation
Modification: phosphorylation
EnrichmentMethod: IMAC
EnrichmentMethod: TiO2 enrichment
MaterialType: protein
MaterialType: protein pellets
AcquisitionMethod: data-dependent higher-energy collision dissociation (HCD)
Instrument: LTQ-Orbitrap-Velos mass spectrometer
IonizationType: nanospray ion source
FragmentationMethod: HCD
CollisionEnergy: normalized collision energy of 42.5
PrecursorMassTolerance: 10 ppm
FragmentMassTolerance: 0.02 Da
MS2MassAnalyzer: Orbitrap
GradientTime: 4 h
Separation: reverse-phase PicoFrit capillary column (75 μm i.d. x 400 mm)
Separation: reverse-phase trap column (0.3 mm i.d. x 1 mm)
FlowRateChromatogram: 0.3 μl/min
AssayName: TMT-labelled samples
AssayName: Compound 2-treated wild-type and mutant phosphoproteomic comparison
AssayName: invasion assay
FactorValue: Compound 2 treatment
Compound: Compound 2 (4-[7-[(dimethylamino)-methyl]-2-(4-fluorphenyl)imidazo[1,2-alpha]pyridine-3-yl] pyrimidin-2-amine)
ConcentrationOfCompound: 2 μM
ConcentrationOfCompound: 10 μM
SamplingTime: 1 h at 37 °C
Temperature: 37 °C
Temperature: 22 °C
TechnicalReplicate: three independent experiments
SourceName: infected RBCs
SourceName: P. falciparum 3D7 parasites